National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 31 of 66
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
NCT01145430
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
NCT01141244
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
NCT01158274
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01132820
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
NCT01143402
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
NCT01154452
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
NCT01195415
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
NCT01159301
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
NCT01160445
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
NCT01142401
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
NCT01134601
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT01130506
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
NCT01132911
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
NCT01130519
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
NCT01119599
ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
NCT01154426
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
NCT01132586
RO4929097 in Treating Patients With Metastatic Colorectal Cancer
NCT01116687
Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers
NCT01021215
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
NCT01126502
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases
NCT01120288
Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses
NCT01194687
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
NCT01109407
Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
NCT00979992
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
NCT01076543
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
NCT01013649
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01074411
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
NCT01105377
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
NCT01132573
Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia
NCT01097304
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
NCT01118091
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
NCT01093222
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01076556
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
NCT01092182
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
NCT01086696
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
NCT01100944
Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
NCT01077453
Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer
NCT00956163
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
NCT00979862
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
NCT01085214
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
NCT00955305
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
NCT01088763
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
NCT01062425
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
NCT01090765
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
NCT00813423
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT01015833
O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma
NCT00961220
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
NCT00980343
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
NCT01100931
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
NCT01076530
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.